signaling (Irf1, Ifnar2, Oas2, Ifi35, and Ifitm1) (31, 32) ( Fig. 4D and fig. S7C ). Expression of these genes was also increased in murine bone marrowderived DCs stimulated with Bifidobacterium in vitro (table S6) , consistent with previous reports that these species of Bifidobacterium can directly elicit DC maturation and cytokine production (13) .
To test whether functional differences in DCs isolated from TAC, JAX, and Bifidobacteriumtreated TAC mice could be sufficient to explain the differences in T cell priming observed in vivo, we purified DCs from lymphoid tissues of naïve TAC, JAX, and Bifidobacterium-treated TAC mice and tested their ability to induce carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled CD8 + SIY-specific 2C TCR Tg T cell proliferation and acquisition of IFN-g production in vitro. DCs purified from JAX and Bifidobacterium-treated TAC mice induced 2C T cell proliferation at lower antigen concentration than did DCs purified from naïve TAC mice (fig. S8, A and B). Furthermore, at all antigen concentrations, JAX-derived DCs elicited elevated levels of T cell IFN-g production ( Fig. 4E and fig. S8A ). We observed similar effects upon oral administration of Bifidobacterium to TAC mice before DC isolation ( Fig. 4E and fig.  S8A ). Taken together, these data suggest that commensal Bifidobacterium-derived signals modulate the activation of DCs in the steady state, which in turn supports improved effector function of tumor-specific CD8 + T cells. Our studies demonstrate an unexpected role for commensal Bifidobacterium in enhancing antitumor immunity in vivo. Given that beneficial effects are observed in multiple tumor settings and that alteration of innate immune function is observed, this improved antitumor immunity could be occurring in an antigen-independent fashion. The necessity for live bacteria may imply that Bifidobacterium colonizes a specific compartment within the gut that enables it to interact with host cells that are critical for modulating DC function or to release soluble factors that disseminate systemically and lead to improved DC function.
Our results do not rule out a contribution of other commensal bacteria species in having the capability to regulate antitumor immunity, either positively or negatively. Our data support the idea that one source of intersubject heterogeneity with regard to spontaneous antitumor immunity and therapeutic effects of antibodies targeting the PD-1/PD-L1 axis may be the composition of gut microbes, which could be manipulated for therapeutic benefit. These principles could apply to other immunotherapies, such as antibodies targeting the CTLA-4 pathway. Similar analyses can be performed in humans, by using 16S rRNA sequencing of stool samples from patients receiving checkpoint blockade or other immunotherapies, to identify commensals associated with clinical benefit. The invasion of a suitable host hepatocyte by mosquito-transmitted Plasmodium sporozoites is an essential early step in successful malaria parasite infection. Yet precisely how sporozoites target their host cell and facilitate productive infection remains largely unknown. We found that the hepatocyte EphA2 receptor was critical for establishing a permissive intracellular replication compartment, the parasitophorous vacuole. Sporozoites productively infected hepatocytes with high EphA2 expression, and the deletion of EphA2 protected mice from liver infection. Lack of host EphA2 phenocopied the lack of the sporozoite proteins P52 and P36. Our data suggest that P36 engages EphA2, which is likely to be a key step in establishing the permissive replication compartment.
M alaria infections place a tremendous burden on global health (1) . Their causative agents, Plasmodium parasites, are transmitted to mammals as sporozoites by the bite of Anopheles mosquitoes. After entry into a capillary, sporozoites are carried to the liver, where they pass through multiple cells before recognizing and invading hepatocytes. During invasion, the sporozoite forms a protective parasitophorous vacuole made of hepatocyte plasma membrane, which ensconces the parasite, establishes the intrahepatocytic replication niche, and supports successful infection. Highly sulfated proteoglycans are known to provide a signal to sporozoites to invade the liver parenchyma (2, 3), and hepatocyte CD81 and scavenger receptor B1 are important for hepatocyte infection (4-6). Beyond this, the molecular mechanisms underlying infection remain poorly understood.
Hepatocytes exhibit differential susceptibility to infection. Sporozoites preferentially enter polyploid hepatocytes (7) . Also, BALB/cByJ mice are more susceptible than BALB/cJ mice to Plasmodium yoelii sporozoite infection (8) . To identify potential host receptors that might contribute to differential susceptibility, we used an antibody array to assess the levels of 28 activated receptors in the livers of BALB/cJ and BALB/cByJ mice. Nine receptors, including EphA2, were present at significantly (P < 0.01) and substantially elevated levels in highly susceptible BALB/cByJ mice (table S1). Polyploid hepatocytes also expressed higher levels of EphA2 ( fig. S1 ).
In metazoans, Eph receptors and their cognate Ephrin ligands mediate cell-cell contact (9), making EphA2 a candidate to mediate the hepatocytesporozoite interaction. Furthermore, an Ephrin-like fold is present in the parasite's 6-Cys protein family (10) . Although Hepa1-6 cells (a murine hepatocyte line) expressed EphA2 consistently across passages, variation within a culture was substantial ( fig. S2 ). We therefore postulated that if EphA2 mediates sporozoite invasion, susceptibilities might vary within a culture of Hepa1-6 cells.
We infected Hepa1-6 cells with P. yoelii sporozoites; after 24 hours, we assessed parasites in hepatocytes that expressed high levels of EphA2 (Fig. 1A) . We also observed this by flow cytometry 1.5 hours after infection (Fig. 1B and fig. S3A ), and parasite-infected cells exhibited significantly increased levels of both total (Fig. 1C) and surface ( fig. S3, B to D (Fig. 1D) . When we included only the top 40, 30, 20, or 10% of EphA2-expressing cells in the EphA2 high gate, the preference was even more pronounced ( fig. S3E) .
We next challenged BALB/c mice with 10 6 P. yoelii sporozoites and isolated hepatocytes after 3 hours. We again observed a strong parasite preference for EphA2 high hepatocytes (Fig. 1, E to G ). Finally, we tested whether the preference for infection of EphA2 high hepatocytes is also present in the human parasites by infecting HC-04 hepatocytes with P. falciparum. We observed elevated levels of EphA2 in infected cells and a higher proportion of sporozoite-containing cells in the EphA2 high population (Fig. 1, H to J). EphA2 has an extracellular ligand-binding region and an intracellular kinase domain, which mediates downstream signaling. To assess whether interaction with the extracellular portion of EphA2 is critical for Plasmodium infection, we infected hepatocytes in the presence of an antibody that binds extracellular EphA2. The presence of the antibody reduced sporozoite infection in a dosedependent manner (Fig. 1K) . In contrast, inhibiting the kinase domain of EphA2 did not inhibit infection ( fig. S4) of infection, the number of EphA2 low infected cells decreased over time (Fig. 2A) . This difference could not be accounted for by division rates, because we observed lower levels of host cell division among EphA2 low cells. Thus, our results may in fact underestimate the impact of EphA2 on infected cell survival ( fig. S5 ). When we infected EphA2 (−/−) and wild-type mice with 10 5 P. yoelii sporozoites, we observed a large decrease in liver-stage burden after 42 hours in EphA2 (−/−) mice (Fig. 2B ).
EphA2
(−/−) mice also exhibited a delay in the onset of blood-stage infection by 1 to 3 days (Fig. 2C) . Thus, without EphA2, the host is far less susceptible to productive parasite liver infection.
The parasitophorous vacuole membrane (PVM) is critical for liver-stage development. One liverstage PVM-resident protein, UIS4, is highly expressed after invasion when it is exported to the PVM (11), making it a useful marker. We constructed a P. yoelii parasite line, PyUIS4-Myc, which expressed a UIS4-Myc fusion protein driven by the endogenous UIS4 promoter (Fig. 2D ). This allowed us to monitor PVM prevalence (UIS4 pos ) in infected cells by flow cytometry. Most of the UIS4 pos infected host cells were in the EphA2 high category (Fig. 2E) . Similarly, the level of EphA2 expression was higher in UIS4 pos infected cells than in UIS4 neg infected cells (Fig. 2F) . Thus, sporozoites not only preferentially entered EphA2 high cells, but invasion accompanied by PVM formation was far more effective in these cells. UIS4 neg infected hepatocytes suffered a higher frequency of cell death (Fig. 2G) .
Two members of the 6-Cys family of parasite proteins (12, 13), P52 and P36, are expressed in sporozoites, are important for the invasion of hepatocytes (14) (15) (16) , and are critical for PVM formation (14) . In mouse livers, parasites without P52 or P36 were almost entirely eliminated within 3 hours after infection ( fig. S6 ). We tested whether the lack of P52 and P36 phenocopies the lack of host EphA2 and found that p52
sporozoites exhibited a reduced preference for EphA2 high cells (Fig. 3A) . The related 6-Cys protein P12 shows structural similarity to the mammalian ligand for EphA2, EphrinA1 (10) .
We showed that an interaction in the extracellular region of EphA2 was required for sporozoite entry using an EphA2-blocking antibody (Fig.  1K) . Therefore, we next asked whether the presence of P36 and P52 was required for the antibody to block sporozoite entry. The EphA2 antibody blocked infection for wild-type P. yoelii sporozoites, but p52 -/p36
-sporozoite entry was not affected (Fig. 3B ). These data suggest that P36 or P52 engages EphA2 at the point of host cell invasion. We next tested whether P52 or P36 could directly impede the interaction between EphrinA1 and EphA2 on the hepatocyte surface, which results in EphA2 activation. When we added EphrinA1 in the presence of P36 to Hepa1-6 cells, P36 blocked the activation of EphA2 (Fig. 3,  C and D) . P52, however, did not block EphrinA1-mediated activation of EphA2 (Fig. 3, C and D) .
To determine whether the interaction between EphA2 and P36 also occurs in human parasites, we assessed levels of EphA2 in P. falciparum wild-type or p52
HC-04 cells. The P52-P36-deficient P. falciparum sporozoites exhibited partially reduced selectivity for EphA2 high HC-04 cells compared with P. falciparum wild-type sporozoites (Fig. 3E) . Thus, P36 engages EphA2 but does not trigger its activation in rodent and human parasites.
We have shown that both host EphA2 and parasite 6-Cys proteins have a role in sporozoite invasion of hepatocytes and the establishment of the growth-permissive intracellular niche. Without either component, the parasite can still enter hepatocytes, but it does so without a PVM, which can result in death of the infected hepatocyte. The convergence of infection-permissive phenotypes is best explained by an interaction between parasite P36 and hepatocyte EphA2 when the PVM is formed. This role for EphA2 in hepatocyte infection does not preclude the possibility that additional hepatocyte receptors may be critical for infection. Interventional strategies aimed at either EphA2 or sporozoite 6-Cys proteins might block parasite infection before the onset of clinical malaria.
